Zydus Lifesciences gains 3% on USFDA nod for injections to treat neuro disorders

The Edaravone injection is used in the treatment of a certain type of nerve disease termed ‘amyotrophic lateral sclerosis’ (ALS), which is commonly called Lou Gehrig's disease. It’s a fatal motor neuron condition that leads to degeneration of nerve cells in the spinal cord and brain.

Zydus Lifesciences has also received the USFDA final approval for the manufacture and market of Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), single-dose vials.

This injection is used for treating certain mental or mood disorders, such as schizophrenia, psychotic disorders, manic phase of bipolar disorder, severe behavioural problems in children.

It is also indicated to control nausea, relieve prolonged hiccups, relieve restlessness or anxiety before surgery, while also in the treatment of a certain liver problem called porphyria, along with treating tetanus.

Both injections will be produced at Zydus Lifesciences Group’s injectable manufacturing facility located at Jarod, near Vadodara in Gujarat.

As of December 31, 2023, Zydus Lifesciences Group received a total of 390 approvals and has filed more than 460 abbreviated new drug applications (ANDAs) since the process of filing started back in FY 2003–04.

Shares of Zydus Lifesciences were trading 2.88% higher at ₹996.55 apiece on BSE at 1:20 pm.